EUVIMEDEUVIMED entdecken
Crossref

Discovery of Highly Potent and Selective EZH2 Covalent Inhibitors via Incorporating Basic Amines

Yi Zhang, Qiongyu Shi, Wei Fang, Li Liu, Hong Yang, Xinqiao Liu, Yuting Huang, Ying Zhang, Xun Huang, Yuanxiang Wang iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c00545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yi Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Balance-Based Drug Discovery Laboratory, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Amines, Drug Discovery, Antineoplastic Agents. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Program of Shanghai Subject Chief Scientist, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted covalent inhibition is a promising strategy to address the high dose and acquired drug resistance issues of the first-generation EZH2 noncovalent inhibitors. Recently we have reported a new generation of highly potent EZH2 covalent inhibitors, but further optimization to enhance aqueous solubility is required. Here, we described the systematic optimization of EPZ-6438 by preserving the aqueous groups, resulting in the identification of a highly potent and selective EZH2 covalent inhibitor 13, which displayed nanomolar potency in biochemical and cellular assays. Moreover, SAM competition experiments preliminarily confirmed that 13 was noncompetitive with SAM, leading to the remarkable reduction of the H3K27Me3 marker. In addition, 13 exhibited superior cell growth inhibition in the EZH2 mutant cancer cell lines. The discovery of 13 holds promise for the development of highly potent EZH2 covalent inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinAminesDrug DiscoveryAntineoplastic AgentsHumansStructure-Activity RelationshipCell Line, TumorCell ProliferationMolecular Structure

Substanzen

Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanAminesAntineoplastic Agents

Autor:innen und Institutionen

  • Balance-Based Drug Discovery Laboratory, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
  • Lingang Laboratory, Shanghai 200031, P. R. China.
  • School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
  • School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.

ORCID-Profile: Yuanxiang Wang

Förderung

  • Program of Shanghai Subject Chief Scientist
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Y., Shi, Q., Fang, W., Liu, L., Yang, H., Liu, X., Huang, Y., Zhang, Y., Huang, X., & Wang, Y. (2025). Discovery of Highly Potent and Selective EZH2 Covalent Inhibitors via Incorporating Basic Amines. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00545

Vancouver

Zhang Y, Shi Q, Fang W, Liu L, Yang H, Liu X, et al. Discovery of Highly Potent and Selective EZH2 Covalent Inhibitors via Incorporating Basic Amines. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00545

BibTeX
@article{Zhang2025,
  author = {Zhang, Yi and Shi, Qiongyu and Fang, Wei and Liu, Li and Yang, Hong and Liu, Xinqiao and Huang, Yuting and Zhang, Ying and Huang, Xun and Wang, Yuanxiang},
  title = {Discovery of Highly Potent and Selective EZH2 Covalent Inhibitors via Incorporating Basic Amines},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c00545}
}
Kostenlos starten →